Stock Highlights: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), Micron Technology, Inc. (NASDAQ:MU), Agenus Inc. (NASDAQ:AGEN), Zogenix, Inc. (NASDAQ:ZGNX), Renasant Corp. (NASDAQ:RNST)

Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) belongs to Healthcare sector. Its weekly performance is -11.88%. On last trading day company shares ended up $10.53. Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) distance from 50-day simple moving average (SMA50) is -19.19%. On 29 June, Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) announced top-line clinical efficacy results from the metformin arm of an ongoing Phase 2 proof-of-concept clinical trial of BI187004/VTP-34072 in the treatment of overweight type 2 diabetic patients. BI187004/VTP-34072 is a potential first-in-class 11β-hydroxysteroid dehydrogenase type 1 (11β HSD1) inhibitor that was discovered by Vitae and is currently being developed by Boehringer Ingelheim GmbH (Boehringer Ingelheim), a leader in diabetes treatments and cardiometabolic research and development.

Micron Technology, Inc. (NASDAQ:MU) shares advanced 11.36% in last trading session and ended the day at $19.61. MU Gross Margin is 33.50% and its return on assets is 16.00%. Micron Technology, Inc. (NASDAQ:MU) quarterly performance is -29.26%. Micron Technology, Inc. (NASDAQ:MU) announced a new encryption-enhanced solid state drive (SSD) for read-centric data center workloads, accelerating the transition from legacy hard disk drives (HDDs) to higher-performance flash-based storage

On 14 July, Agenus Inc. (NASDAQ:AGEN) shares advanced 1.08% and was closed at $9.32. AGEN EPS growth in last 5 year was 21.40%. Agenus Inc. (NASDAQ:AGEN) year to date (YTD) performance is 134.76%. Agenus Inc. (NASDAQ:AGEN) is now covered by analysts at HC Wainright. They set a “buy” rating and a $14.00 price target on the stock.

Zogenix, Inc. (NASDAQ:ZGNX) ended the last trading day at $17.69. Company weekly volatility is calculated as 10.82% and price to cash ratio as 15.92. Zogenix, Inc. (NASDAQ:ZGNX) showed a weekly performance of 32.51%. Zogenix, Inc. (NASDAQ:ZGNX) said it would delay by three months the start of late-stage trials for its drug to treat a rare form of epilepsy in children. Renasant Corp. (NASDAQ:RNST) shares advanced 0.09% in last trading session and ended the day at $33.56. RNST return on assets is 1.10%. Renasant Corp. (NASDAQ:RNST) quarterly performance is 12.40%.Renasant Corp. (NASDAQ:RNST) announced the formation of a new Healthcare Banking Group.

Leave a Reply

Your email address will not be published. Required fields are marked *